Zai Lab raises $250 million in PIPE and reports 81.8% response rate in Phase 1b ES‑SCLC trial
Zai Lab announced a private placement of 11.34 million American Depositary Shares at $22.04 each, generating $250 million in gross proceeds. The financing, led by TCGX, is expected to close on or about October 27, 2026. In the same announcement the company disclosed Phase 1b data for its DLL3‑targeting ADC zocilurtatug pelitecan (zoci) combined with atezolizumab, showing an 81.8% confirmed objective response rate and an 81.9% six‑month progression‑free survival in first‑line extensive‑stage small‑cell lung cancer. Grade > 3 adverse events related to zoci occurred in 9.1% of patients. Zai Lab said a global randomized Phase 3 trial will start by year‑end 2026.
Why it matters
The $250 million PIPE provides funding to advance zoci’s global development and other corporate initiatives. The strong early efficacy and safety signals support the upcoming Phase 3 trial, which could enhance the company’s oncology pipeline and affect its valuation.
Key facts
- 1Zai Lab raised $250 million by selling 11.34 million ADS at $22.04 each. tradingview.com
- 2The private placement is expected to close on or about October 27, 2026, subject to conditions. tradingview.com
- 3The Phase 1b trial reported a confirmed objective response rate of 81.8% (27/33) for zoci plus atezolizumab. stocktitan.net
- 4Six‑month progression‑free survival was 81.9% in the same cohort. stocktitan.net
- 5Grade > 3 adverse events related to zoci occurred in 9.1% of patients (3/33). stocktitan.net
- 6A global randomized Phase 3 study in first‑line ES‑SCLC is planned to start by year‑end 2026. stocktitan.net
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.